Europe / 5 Rare Disease Start-Ups to Watch
With Rare Disease Day falling on 28 February, PharmaBoardroom dedicates this month to exploring the global rare disease landscape, highlighting key trends and developments as well as profiling the most…
With Rare Disease Day falling on 28 February, PharmaBoardroom dedicates this month to exploring the global rare disease landscape, highlighting key trends and developments as well as profiling the most…
Advances in cell and gene therapies (CGT) are credited with thoroughly transforming medicinal science and creating an inflection point in the ability to treat and potentially cure many intractable illnesses.…
A trained physician with several years of practice under her belt, Katharina Gasser then moved into clinical research as an investigator before joining the pharma industry in 2005. Now head…
Alvotech – the biosimilars arm of Icelandic-headquartered generics player Alvogen – is positioning itself for future growth via a very different strategy to that of the Big Pharma players with…
The Brazilian pharma market outperformed the Latin American average in Q1 of 2020 with a growth of 8.2 percent in real terms (inflation adjusted), according to IQVIA. Its size reached…
Bayer’s Michael Levy casts his eye over the implications of the advent of cell and gene therapies on pharmacovigilance and patient safety. Levy examines why these potentially revolutionary new therapies…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact that a de facto annual review has had on drug approval timelines, and why…
The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in the latest national budget; predictions of rapid growth in the coming decade; Cipla’s…
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug expenditures in 2018, the world’s second-largest pharma market has steadily expanded the 4+7 pilot program into…
The ascent of cell and gene therapies (CGT) is commonly regarded as one of the momentous turning points in the history of the pharmaceuticals industry. Not only do innovative therapies…
While perhaps not as lucrative or – prior to COVID-19 – as attention-grabbing – as other areas of the pharmaceutical industry, vaccines are also not the forgotten backwaters that many…
Emerging cell and gene therapies herald immense clinical value for patients, society, and healthcare systems: carrying the potential to offer life-changing solutions for people with few or no alternative treatments.…
See our Cookie Privacy Policy Here